FDA Alert: FDA Restricts Use of Ocaliva (obeticholic acid) in Primary Biliary Cholangitis Patients with Advanced Cirrhosis Due to Risk of Serious Liver Injury

FDA Alert: FDA Restricts Use of Ocaliva (obeticholic acid) in Primary Biliary Cholangitis Patients with Advanced Cirrhosis Due to Risk of Serious Liver Injury

Comments

Popular posts from this blog

Dams, taps running dry in northern Mexico amid historic water shortages | Nasdaq

The conflict in Gaza: a view from Israel - The Lancet